Read twice and referred to the Committee on Finance.
The bill requires Medicare, Medicaid, and CHIP to cover specified cancer diagnostic and laboratory tests—defined to include microarray, DNA/RNA sequencing, whole-exome sequencing, and interpretation—on set timetables. It sets Medicare payment rules (generally 80% of lesser of actual charge or a comparative rate, 100% in some assignment cases), removes the Part B deductible for these tests, limits repeat testing frequency, mandates Medicaid and CHIP inclusion (CHIP effective 2025, Medicaid effective 2027), and directs HHS and the National Human Genome Research Institute to run genomic testing education programs and encourage clinician training.
Support: access to precision diagnostics vs concern: expanded federal spending
Technocratic benefit expansion with bipartisan appeal but creates uncapped entitlement costs and lacks offset.
The bill requires Medicare, Medicaid, and CHIP to cover specified cancer diagnostic and laboratory tests—defined to include microarray, DNA/RNA sequencing, whole-exome sequencing, and interpretation—on set timetables.
It sets Medicare payment rules (generally 80% of lesser of actual charge or a comparative rate, 100% in some assignment cases), removes the Part B deductible for these tests, limits repeat testing frequency, mandates Medicaid and CHIP inclusion (CHIP effective 2025, Medicaid effective 2027), and directs HHS and the National Human Genome Research Institute to run genomic testing education programs and encourage clinician training.
Technically narrow and non-ideological so it can attract support, but entitlement cost increases and absence of offsets reduce standalone prospects.
How solid the drafting looks.
Support: access to precision diagnostics vs concern: expanded federal spending
These are examples from the analysis, not a ranked list of the most-affected groups.
Support: access to precision diagnostics vs concern: expanded federal spending
Likely broadly supportive because the bill expands access to advanced genomic testing for cancer patients and reduces financial barriers.
It aligns with goals of equity in care and precision medicine, while including public education and clinician training.
Cautiously supportive: the bill advances diagnostic capacity and patient information but raises questions about costs, payment mechanics, and program integrity.
Would favor amendments clarifying reimbursement, utilization guardrails, and fiscal offsets.
Likely generally opposed due to new federal mandates, expanded entitlement spending, and potential state preemption.
Concerns include long-term costs, overuse, and reduced state flexibility for Medicaid.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow and non-ideological so it can attract support, but entitlement cost increases and absence of offsets reduce standalone prospects.
The bill has not accumulated any surfaced votes yet.
Support: access to precision diagnostics vs concern: expanded federal spending
Technically narrow and non-ideological so it can attract support, but entitlement cost increases and absence of offsets reduce standalone p…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Finn Sawyer Access to Cancer Testing Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.